These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 24589868)
21. Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone. Zech G; Hessler G; Evers A; Weiss T; Florian P; Just M; Czech J; Czechtizky W; Görlitzer J; Ruf S; Kohlmann M; Nazaré M J Med Chem; 2012 Oct; 55(20):8615-29. PubMed ID: 22984835 [TBL] [Abstract][Full Text] [Related]
22. Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: An ex vivo study. Bonhomme F; Bonvini R; Reny JL; Poncet A; Fontana P Platelets; 2015; 26(4):324-30. PubMed ID: 25905916 [TBL] [Abstract][Full Text] [Related]
23. Progress in platelet blockers: the target is the P2Y12 receptor. Patel PA; Lane B; Augoustides JG J Cardiothorac Vasc Anesth; 2013 Jun; 27(3):620-4. PubMed ID: 23672863 [TBL] [Abstract][Full Text] [Related]
24. Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor. Hobl EL; Derhaschnig U; Firbas C; Schoergenhofer C; Schwameis M; Jilma B Eur J Clin Invest; 2013 Dec; 43(12):1258-61. PubMed ID: 24112116 [TBL] [Abstract][Full Text] [Related]
25. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Yanachkov IB; Chang H; Yanachkova MI; Dix EJ; Berny-Lang MA; Gremmel T; Michelson AD; Wright GE; Frelinger AL Eur J Med Chem; 2016 Jan; 107():204-18. PubMed ID: 26588064 [TBL] [Abstract][Full Text] [Related]
27. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169 [TBL] [Abstract][Full Text] [Related]
28. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. Tomasello SD; Tello-Montoliu A; Angiolillo DJ Expert Opin Investig Drugs; 2011 Jan; 20(1):119-33. PubMed ID: 21143003 [TBL] [Abstract][Full Text] [Related]
30. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor. Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131 [TBL] [Abstract][Full Text] [Related]
31. [Genetic variability in the efficacy of clopidogrel]. Kristensen KE; Rasmussen HB; Hansen PR Ugeskr Laeger; 2013 Mar; 175(11):729-32. PubMed ID: 23480885 [TBL] [Abstract][Full Text] [Related]
32. Assessment of steady-state clopidogrel reactivity by using platelet reactivity units. Rasool S; Khalaf H; Almeman A; AlOrainy MM Am J Ther; 2015; 22(3):182-5. PubMed ID: 25768377 [TBL] [Abstract][Full Text] [Related]
33. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. Nylander S; Femia EA; Scavone M; Berntsson P; Asztély AK; Nelander K; Löfgren L; Nilsson RG; Cattaneo M J Thromb Haemost; 2013 Oct; 11(10):1867-76. PubMed ID: 23890048 [TBL] [Abstract][Full Text] [Related]
34. Advances in the monitoring of anti-P2Y12 therapy. Harrison P Platelets; 2012; 23(7):510-25. PubMed ID: 22916724 [TBL] [Abstract][Full Text] [Related]
35. Potassium 2-(1-hydroxypentyl)-benzoate inhibits ADP-induced rat platelet aggregation through P2Y1-PLC signaling pathways. Yang H; Xu S; Li J; Wang L; Wang X Naunyn Schmiedebergs Arch Pharmacol; 2015 Sep; 388(9):983-90. PubMed ID: 25787305 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827 [TBL] [Abstract][Full Text] [Related]
37. Prasugrel Hydrochloride. Al Omari MM; Qinna NA; Rashid IS; Al-Sou'od KA; Badwan AA Profiles Drug Subst Excip Relat Methodol; 2015; 40():195-320. PubMed ID: 26051687 [TBL] [Abstract][Full Text] [Related]
38. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412 [TBL] [Abstract][Full Text] [Related]
39. The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. Jakubowski JA; Erlinge D; Alexopoulos D; Small DS; Winters KJ; Gurbel PA; Angiolillo DJ Am J Cardiovasc Drugs; 2017 Apr; 17(2):109-121. PubMed ID: 27854064 [TBL] [Abstract][Full Text] [Related]
40. Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents. Migliorini A; Valenti R; Parodi G; Marcucci R; Abbate R; Carrabba N; Gensini GF; Antoniucci D Am J Cardiol; 2013 Dec; 112(12):1843-8. PubMed ID: 24063827 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]